State Street Corp Aprea Therapeutics, Inc. Transaction History

State Street Corp

$2.25 Trillion
Q2 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$0.38 - $8.2 $15,516 - $334,822	-40,832 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.05 - $5.5 $339,228 - $460,680	-83,760 Reduced 67.23%	40,832 $199,000
Q1 2021 May 17, 2021	SELL	$4.73 - $8.15 $42,262 - $72,820	-8,935 Reduced 6.69%	124,592 $635,000
Q4 2020 Feb 16, 2021	BUY	$4.92 - $30.67 $26,641 - $166,078	5,415 Added 4.23%	133,527 $657,000
Q3 2020 Nov 10, 2020	BUY	$21.66 - $38.86 $112,047 - $201,022	5,173 Added 4.21%	128,112 $3.08 Million
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $297,133 - $463,023	11,666 Added 10.48%	122,939 $4.77 Million
Q1 2020 May 11, 2020	BUY	$31.65 - $45.3 $3.52 Million - $5.04 Million	111,273 New	111,273 $3.87 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,472
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.